Expected improvement in treatment effectiveness and production … Will be applied to clinical trials on injective arthritis medicine
On November 8, MEDIPOST announced that has obtained a patent on next-generation method for culturing stem cells that can improve the effectiveness and production efficiency of stem cells.
The tile of this patent is ‘Method for Culturing Mesenchymal Stem Cells’, and it is about how to culture the stem cells with improved growth, survival, recovery rate, aging resistance, and immune suppression.
MEDIPOST is using this patent technology in culturing process of highly effective stem cell ‘SMUP-Cell’ under its research and plans to apply it to new pipelines.
Especially, the culture technology is being applied to develop ‘injection degenerative arthritis drug’ which is being developed with the aim of applying for clinical tests next year.
MEDIPOST already had obtained patents on this culture technology in Korea (2015) and USA (2017).
Medipost official said, “by this patent, we improved our existing process and secured a basic technology that can mass-produce highly effective mesenchymal stem cells.”.